When JNJ acquired Cordis, the logic seemed to be that JNJ's dominance in coronary stents would benefit Cordis by increasing their share in PTCA balloons. Has that happened? I'm led to believe that Cordis' market share has actually declined since the acquisition? Is that true? If so, what benefit did JNJ get from the tremendous premium that was paid for Cordis?